US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
GlobalData on MSN5d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
News Medical on MSN5d
New HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback